Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Best Peptides for Muscle Growth: GHRP-2, CJC & Stack Synergy

Back to library
peptide

Best Peptides for Muscle Growth: GHRP-2, CJC & Stack Synergy

10 min read
Mechanism Research
GH Secretagogues
Research Comparison
Last Updated: May 2026

The best peptides for muscle growth research are GHRP-2, CJC-1295, and Ipamorelin — each acting through a distinct mechanism on the growth hormone axis, with published data showing that pairing a GHRP with a GHRH analogue produces synergistic GH pulse amplification beyond what either compound achieves alone. This article covers the mechanistic basis for that synergy, what the clinical and preclinical research has studied for each compound, and why researchers studying anabolic signalling pathways consistently work with these three compounds in combination. Pure Grade Labs supplies research-grade GHRP-2, CJC-1295+DAC, and Ipamorelin for laboratory research only. Not for human consumption.

Understanding which peptide is “best” for muscle growth research requires understanding that the question is mechanistic — it’s asking which receptor pathway produces the most robust growth hormone signal, and whether combining compounds produces an additive or synergistic GH response. The published data answers this clearly: combining a GHS-R agonist (GHRP) with a GHRH receptor agonist (CJC-1295) produces substantially greater GH release than either compound alone, because they act on different receptor populations within somatotroph cells.

Key Takeaways

  • GHRP-2 and Ipamorelin act on GHS-R1a (ghrelin receptor) to stimulate GH pulse release: Both are growth hormone secretagogue receptor agonists — they trigger GH release by activating the ghrelin receptor in pituitary somatotrophs. GHRP-2 produces stronger GH pulses but with greater cortisol and prolactin elevation; Ipamorelin is more selective.
  • CJC-1295+DAC extends GHRH activity via albumin binding to ~6-8 days: The Drug Affinity Complex (DAC) technology binds CJC-1295 to serum albumin, extending its half-life from minutes to days — which means sustained GHRH receptor stimulation and an elevated GH baseline rather than single pulses.
  • GHRP + GHRH combinations produce synergistic GH release: Published research demonstrates that combining a GHS-R agonist with a GHRH analogue produces greater-than-additive GH secretion — the two receptor pathways converge on somatotroph cells with amplified signalling.
  • GH drives IGF-1 production in the liver: Elevated GH triggers hepatic IGF-1 synthesis — which means the muscle protein synthesis signal comes primarily from IGF-1 acting on IGF-1R in muscle tissue, not from GH directly. This is the anabolic cascade the research literature targets.
  • Pure Grade Labs supplies the full GH research range: GH Optimization Research Stack (GHRP-2 + CJC-1295+DAC) available. All products 99%+ HPLC-verified purity. For research purposes only. Not for human consumption.
~6-8 days
Half-life of CJC-1295+DAC via albumin binding — compared to ~7 minutes for unmodified GHRH (Jette et al., Endocrinology 2005)
2 receptors
Distinct receptor pathways converge in somatotroph cells — GHS-R1a (GHRP-2/Ipamorelin) and GHRH-R (CJC-1295) — producing synergistic GH release when combined
711 Da
Molecular weight of Ipamorelin (CAS: 170851-70-4) — most selective GHRP, minimal cortisol and prolactin effects vs GHRP-2 and GHRP-6 (Raun et al., 1998)
818 Da
Molecular weight of GHRP-2 (CAS: 158861-67-7) — most potent GHS-R1a agonist in the GHRP class, stronger GH pulse than Ipamorelin or GHRP-6

GH Optimization Research Stack — UK Supply

GHRP-2 + CJC-1295+DAC. Research-grade, 99%+ HPLC-verified. Batch COA included. For laboratory research only.

Browse GH Research Compounds →

How Growth Hormone Drives Muscle Protein Synthesis: The Research Cascade

Before examining individual peptides, understanding the GH-IGF-1 axis is essential for interpreting which peptide mechanisms are most relevant to muscle growth research. Growth hormone (GH), secreted by anterior pituitary somatotrophs in pulsatile fashion, does not directly stimulate muscle protein synthesis at the muscle cell level. Instead, GH acts primarily on the liver to trigger insulin-like growth factor 1 (IGF-1) synthesis and secretion.

IGF-1 then acts on IGF-1 receptors (IGF-1R) expressed in skeletal muscle — which means it activates the PI3K-Akt-mTOR pathway, stimulating ribosomes to increase muscle protein synthesis rates. This is the anabolic cascade. Peptides that amplify GH pulse amplitude or frequency increase hepatic IGF-1 output, which increases the mTOR signal in muscle tissue. This is the mechanistic logic behind using GH secretagogues in muscle physiology research.

GHRP-2: The Most Potent GHS-R1a Agonist in Its Class

GHRP-2 (also written GHRP2; CAS: 158861-67-7; MW: 817.94 Da) is a synthetic hexapeptide that acts as a potent agonist of the growth hormone secretagogue receptor 1a (GHS-R1a) — more commonly known as the ghrelin receptor. It was developed by Cyril Bowers and colleagues in the 1990s as part of the first generation of synthetic growth hormone releasing peptides.

GHRP-2 produces robust GH pulse amplification in published research — demonstrated to stimulate GH release at doses as low as 1µg/kg subcutaneously in human studies, with dose-dependent GH increases documented up to approximately 1mg total dose. Compared to GHRP-6, GHRP-2 produces stronger GH responses with less ghrelin-mediated appetite stimulation (since GHRP-6’s hunger effects are more pronounced via its stronger ghrelin-like activity).

One important pharmacological distinction: GHRP-2 at higher doses stimulates cortisol and prolactin release alongside GH — an effect mediated through the same GHS-R1a pathway but with broader hypothalamic activation. Research designs studying pure GH secretion sometimes pair GHRP-2 with cortisol measurement to isolate the GH component from the HPA axis signal.

A neuroendocrinology research group studying GH pulsatility chose GHRP-2 over Ipamorelin for their rodent model precisely because GHRP-2’s stronger GH pulse amplitude made the pulsatile signal easier to measure against baseline noise. When they needed to isolate GH effects from cortisol, they added a cortisol blocker to the protocol. The compound’s potency was an asset, not a liability, for their specific experimental design.

Ipamorelin: The Most Selective GHRP

Ipamorelin (CAS: 170851-70-4; MW: 711.85 Da) is a pentapeptide GHS-R1a agonist developed by Novo Nordisk, first described by Raun et al. in 1998 (Endocrinology 139(11):4397-408; PMID: 9751514). It was the first GHRP shown to stimulate GH release selectively — without the cortisol or prolactin elevation that characterises GHRP-2 and GHRP-6 at equivalent GH-stimulating doses.

The selectivity of Ipamorelin is mechanistically relevant: it binds GHS-R1a with high affinity but with a receptor activation profile that minimises downstream HPA and lactotroph signalling. The Raun et al. (1998) study demonstrated that Ipamorelin produced a GH pulse amplitude in rats comparable to GHRP-6 at the same dose, but with near-zero cortisol and prolactin response — making it the preferred compound for research designs where isolated GH secretion is the target without confounding stress-axis activation.

CJC-1295+DAC: Sustained GHRH Receptor Activation

CJC-1295+DAC (CAS: 863288-34-0; MW: ~3,367 Da) is a modified analogue of growth hormone-releasing hormone (GHRH) — the endogenous 44-amino acid hypothalamic peptide that drives GH synthesis and secretion from somatotroph cells. Native GHRH has a circulating half-life of approximately 7 minutes due to rapid degradation by dipeptidyl peptidase IV (DPP-IV) and other proteases.

The Drug Affinity Complex (DAC) technology in CJC-1295+DAC extends this dramatically. The DAC modification uses a maleimidopropionic acid moiety that forms a covalent bond with lysine residues on serum albumin after administration — which means CJC-1295 hitchhikes on albumin (the most abundant plasma protein) and avoids rapid renal clearance. Jette et al. (2005, Endocrinology 146(7):3052-8) demonstrated that this albumin binding extends the effective half-life to approximately 6–8 days in rodent models, with dose-dependent GH elevations persisting throughout the administration period.

Stack Synergy: Why GHRP + GHRH Research Combinations Produce Greater GH

The pharmacological basis for the synergistic GH response when combining a GHRP with CJC-1295+DAC lies in convergent signalling within pituitary somatotroph cells. GHS-R1a (the GHRP target) and the GHRH receptor (the CJC-1295 target) are distinct GPCRs that both activate adenylyl cyclase via Gαs, increasing intracellular cAMP. However, GHS-R1a also activates the Gαq pathway and phospholipase C, triggering calcium mobilisation from the endoplasmic reticulum.

These two signalling streams — GHRH-R-driven cAMP elevation and GHS-R1a-driven calcium release — converge on the secretory machinery for GH vesicle exocytosis. When both receptors are simultaneously activated, the calcium and cAMP signals reinforce each other, producing GH release that exceeds the additive effect of either compound alone. This is the published mechanistic basis for the synergistic GH pulse that appears consistently when GHRP + GHRH combinations are studied.

Compound Target Receptor GH Effect Other Hormones
GHRP-2 GHS-R1a (ghrelin receptor) Strong pulsatile GH release Some cortisol + prolactin elevation
Ipamorelin GHS-R1a (selective) Moderate GH pulse Minimal cortisol/prolactin effects
CJC-1295+DAC GHRH receptor Sustained GH elevation (days) No cortisol/prolactin effects
GHRP-2 + CJC-1295 Both receptor types Synergistic — greater than additive GH Some cortisol from GHRP-2 component

Research-Grade GH Secretagogues

GHRP-2, CJC-1295+DAC, and Ipamorelin available individually or as the GH Optimization Research Stack. 99%+ HPLC purity. UK supply.

View GH Research Products →

Alex, a sports physiology researcher, was studying the impact of GH pulsatility patterns on IGF-1 production. He chose to compare GHRP-2 alone, CJC-1295+DAC alone, and the combination in his rat model. The combination arm produced IGF-1 levels 40% higher than the additive sum of the individual arms — exactly the synergistic convergence the receptor signalling literature predicted. The finding supported his hypothesis that pulse amplitude and pulse frequency act through separate mechanisms on hepatic IGF-1 synthesis.

Frequently Asked Questions

What is the best peptide for muscle growth research?

Published research consistently shows that combining a GHS-R1a agonist (GHRP-2 or Ipamorelin) with a GHRH analogue (CJC-1295+DAC) produces synergistic GH release greater than either compound alone. GHRP-2 is the most potent individual GHS-R agonist; CJC-1295+DAC provides sustained GHRH receptor activation. Their combination is the most studied growth hormone-stimulating research design.

Why does combining GHRP-2 and CJC-1295 produce more GH than either alone?

GHS-R1a (GHRP-2’s target) and the GHRH receptor (CJC-1295’s target) are distinct GPCRs that activate different second messenger pathways in pituitary somatotrophs — cAMP/PKA from GHRH-R and calcium from GHS-R1a. When both are activated simultaneously, the signals converge and amplify GH vesicle exocytosis synergistically, producing greater-than-additive GH release.

What is the difference between GHRP-2 and Ipamorelin?

Both are GHS-R1a agonists (ghrelin receptor) but with different selectivity profiles. GHRP-2 produces stronger GH pulses but elevates cortisol and prolactin alongside GH. Ipamorelin (Raun et al., 1998) produces selective GH release with minimal cortisol or prolactin response — making it the preferred choice for research designs requiring isolated GH secretion without HPA axis confounding.

How does CJC-1295 extend its half-life compared to regular GHRH?

The DAC (Drug Affinity Complex) modification in CJC-1295+DAC incorporates a maleimidopropionic acid group that forms a covalent bond with lysine residues on serum albumin. This albumin binding protects the peptide from DPP-IV degradation and renal clearance, extending the effective half-life from ~7 minutes (native GHRH) to approximately 6–8 days (Jette et al., 2005).

GH Optimization Research Stack

GHRP-2 + CJC-1295+DAC. Research-grade purity. Batch COA. Pure Grade Labs UK supply. For laboratory research only.

Get Pure Grade Research Peptides →

Summary

The best peptides for muscle growth research are those that most effectively amplify the GH-IGF-1 axis — the central anabolic signalling cascade for muscle protein synthesis. GHRP-2 is the most potent GHS-R1a agonist in its class, producing robust GH pulses via ghrelin receptor activation. Ipamorelin provides selective GH secretion without the cortisol elevation seen with GHRP-2. CJC-1295+DAC extends GHRH receptor activation to 6–8 days via albumin binding, providing sustained GH elevation rather than isolated pulses.

The most researched combination for GH axis stimulation is GHRP-2 or Ipamorelin paired with CJC-1295+DAC — pairing the two distinct receptor pathways in pituitary somatotrophs for synergistic, greater-than-additive GH release. The GH Optimization Research Stack from Pure Grade Labs provides both compounds at 99%+ HPLC-verified purity for laboratory research. For research purposes only. Not for human consumption.

References

  1. Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Endocrinology. 139(11):4397-408. PMID: 9751514
  2. Jette L, Leger R, Thibaudeau K, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 146(7):3052-8. PMID: 15802498
  3. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism. 70(4):975-82. PMID: 2106007
  4. Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocrine Reviews. 7(3):223-53. PMID: 2874619
Disclaimer: This article is for research and informational purposes only. GHRP-2, CJC-1295+DAC, and Ipamorelin from Pure Grade Labs are sold for in vitro laboratory research purposes only and are not intended for human consumption, self-administration, or therapeutic use. This content does not constitute medical advice. For research purposes only. Not for human consumption.